New drugs in non-Hodgkin's lymphoma.
While novel agents designed to target molecular abnormalities involved in lymphoma pathogenesis are most likely to improve current therapeutic results, cytotoxic therapy remains the main-stay of therapy. Several new chemotherapy agents, including purine antimetabolites, taxanes, camptothecins, suramin, and protein kinase C inhibitors, are discussed. Other issues important in lymphoma drug development, including the limited patient population available for evaluation of investigational agents, are also considered.
Arbuck
S G
SG
Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.
Sorensen
J M
JM
Christian
M C
MC
Ho
P
P
Pluda
J M
JM
Cheson
B D
BD
D000241:Adenosine / Q000031:analogs & derivatives; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D054713:Bryostatins; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D018942:Macrolides; D013498:Suramin / Q000627:therapeutic use; D059004:Topoisomerase I Inhibitors
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D054713:Bryostatins; D004791:Enzyme Inhibitors; D007783:Lactones; D018942:Macrolides; D059004:Topoisomerase I Inhibitors; C046785:bryostatin 1; D013498:Suramin; D000241:Adenosine